Abstract
Since more than 35 years, the international medical scientific community tries to solve the problem of the offlabel use of paediatric drugs. The aim is simple, but ambitious: to supply children and adolescents with effective drugs, as safe as possible, with known and well-documented side effects, and with accurate and up-to-date information on dosage and administration form. However, despite the significant efforts of paediatricians, researchers and international health politics, a number of severe obstacles for the optimal supply of children and adolescents with safe drugs remain. The detailed analysis of the problem shows not only a still remaining lack of medical knowledge, but also persistent weaknesses in the ethical, legal, medical, pharmacological, and political practices that surround the phenomenon of off-label use in paediatrics. The article gives an overview about the remaining difficulties in the field of paediatric off-label medication with special consideration to ethical and regulatory questions.
Keywords: Ethical and legal regulation, off-label use, paediatrics, effective drugs, dosage, children, adolescents, unlicensed drug, Pediatric Rule, quality and safety
Current Drug Targets
Title:Off-Label Drug Use in Paediatrics: A World-Wide Problem
Volume: 13 Issue: 7
Author(s): Christian Lenk
Affiliation:
Keywords: Ethical and legal regulation, off-label use, paediatrics, effective drugs, dosage, children, adolescents, unlicensed drug, Pediatric Rule, quality and safety
Abstract: Since more than 35 years, the international medical scientific community tries to solve the problem of the offlabel use of paediatric drugs. The aim is simple, but ambitious: to supply children and adolescents with effective drugs, as safe as possible, with known and well-documented side effects, and with accurate and up-to-date information on dosage and administration form. However, despite the significant efforts of paediatricians, researchers and international health politics, a number of severe obstacles for the optimal supply of children and adolescents with safe drugs remain. The detailed analysis of the problem shows not only a still remaining lack of medical knowledge, but also persistent weaknesses in the ethical, legal, medical, pharmacological, and political practices that surround the phenomenon of off-label use in paediatrics. The article gives an overview about the remaining difficulties in the field of paediatric off-label medication with special consideration to ethical and regulatory questions.
Export Options
About this article
Cite this article as:
Lenk Christian, Off-Label Drug Use in Paediatrics: A World-Wide Problem, Current Drug Targets 2012; 13 (7) . https://dx.doi.org/10.2174/138945012800675759
DOI https://dx.doi.org/10.2174/138945012800675759 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design Adenosine and Adenosine Receptors in the Pathomechanism and Treatment of Respiratory Diseases
Current Medicinal Chemistry Acetaminophen (Paracetamol) and Injury in the Cardiovascular System
Vascular Disease Prevention (Discontinued) Mechanisms of Enhanced Vasoconstriction in the Mouse Model of Atherosclerosis: the Beneficial Effects of Sildenafil
Current Pharmaceutical Biotechnology Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Solution NMR Study of the Transmembrane Domain of Single-Span Membrane Proteins: Opportunities and Strategies
Current Protein & Peptide Science The Neuronal Histaminergic System in Cognition
Current Medicinal Chemistry - Central Nervous System Agents Toward a Design of Affordable, Topical Microbicides: Acylcarnitine Analogues
Current Pharmaceutical Design Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management
Current Pharmaceutical Design Neuronal Nicotinic Receptors as Brain Targets for Pharmacotherapy of Drug Addiction
CNS & Neurological Disorders - Drug Targets Mast Cells: Pivotal Players in Cardiovascular Diseases
Current Cardiology Reviews Ullrich Congenital Dystrophy and Bethlem Myopathy: Current Knowledge on the Clinical Spectrum, Pathogenesis, and Future Therapeutic Avenues of Collagen VI Related Muscular Dystrophies
Current Pediatric Reviews Paving Roads for New Drugs in Oncology
Recent Patents on Anti-Cancer Drug Discovery Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Current Pharmaceutical Design Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?
Current Pharmaceutical Design Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Pharmacologic Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology